Overview

Lansoprazole 30 mg DR Capsule Fasting Study

Status:
Completed

Trial end date:
2004-07-01

Target enrollment:

Participant gender:

Summary

The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of PREVACID® capsules (TAP Pharmaceuticals, Inc.) in healthy, adult, subjects under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Pharmaceuticals USA

Treatments:

Dexlansoprazole
Lansoprazole